BiVictriX Therapeutics PLC Result of General Meeting (7024I)

TIDMBVX

RNS Number : 7024I

BiVictriX Therapeutics PLC

08 August 2023

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF THE EU REGULATION 596/2014 AS IT FORMS PART OF THE UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

Result of General Meeting

Completion of Fundraise

Total Voting Rights

Alderley Park, 8 August 2023 - BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a differentiated approach to develop next-generation cancer therapies with substantially improved cancer cell selectivity and anti-cancer activity, announces that at the Company's General Meeting held today at 11:00 a.m. at the Company's registered office, Mereside Alderly Park, Alderly Edge, Manchester SK10 4TG, all resolutions were duly passed. Further details of each of the resolutions are set out in the Circular and Notice of Meeting, which was sent to shareholders on 20 July 2023 (the "Circular").

Details of proxy votes received are summarised below:

 
 R esolution                          V otes       Votes Against   Discretionary   Withheld 
                                       For                          Votes 
 Ordinary Resolution 
 In accordance with sec ti 
  on 551 of the Companies 
  Act 2006, the directors 
  of the Company in addi ti 
  on to all previous authori 
  ti es granted to the Directors, 
  be generally and uncondi 
  ti onally authorised to 
  exercise all the powers 
  of the Company to allot 
  shares in the Company, and 
  grant rights to subscribe 
  for or convert any securi 
  ti es into shares in the 
  Company, up to an aggregate 
  nominal amount of GBP164,108.87 
  (within the meaning of sec 
  ti ons 551(3) and (6) of 
  the said Act), in connec 
  ti on with the Fundraise 
  detailed in the Circular.           20,010,176   1               -               - 
                                     -----------  --------------  --------------  --------- 
 Special Resolution 
 In accordance with sec ti 
  on 570 of the Act, the Directors 
  be generally empowered to 
  allot equity securi ti es 
  (as de fi ned in sec ti 
  on 560(1) of the Act) which 
  are the subject of the authority 
  conferred by resolu ti on 
  1 as if sec ti on 561 of 
  the Act did not apply to 
  such allotment, provided 
  that this power shall be 
  limited to the allotment 
  of equity securi ti es up 
  to an aggregate nominal 
  amount of GBP164,108.87, 
  in connec ti on with the 
  Fundraise detailed in the 
  Circular.                           20,010,176   1               -               - 
                                     -----------  --------------  --------------  ---------

Completion of Fundraise

The Resolutions were necessary to implement the Fundraise to raise a total of GBP2.1 million (before expenses), as announced by the Company on 19 July 2023.

Following the passing of the Resolutions, the Company has allotted (subject only to Admission) the Placing Shares and the Subscription Shares with new and existing investors (the "New Ordinary Shares"). The New Ordinary Shares will rank pari passu with the Company's Existing Ordinary Shares.

Admission to AIM and Total Voting Rights

Application has been made for the Admission of 16,410,887 New Ordinary Shares. It is expected that Admission will take place and that trading in the New Ordinary Shares will commence, at 8.00 a.m. on 10 August 2023.

Following Admission, the Company's issued and fully paid share capital will consist of 82,526,088 Ordinary Shares. The Company has no Ordinary Shares in treasury. As such, the total number of voting rights in the Company will be 82,526,088 Ordinary Shares. Following Admission, this number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Note

This announcement should be read in conjunction with the full text of the Circular sent to shareholders on 20 July 2023 in connection with the Fundraise. Capitalised terms used but not otherwise defined in this announcement bear the meanings ascribed to them in the Circular.

 
 For more information, please contact: 
   BiVictriX Therapeutics plc 
   Tiffany Thorn, Chief Executive Officer 
    Michael Kauffman, Non-Executive Chairman     Email: info@bivictrix.com 
 
   SP Angel Corporate Finance LLP (NOMAD        Tel: +44 (0) 20 3470 
    and Broker)                                  0470 
   David Hignell, Kasia Brzozowska (Corporate 
    Finance) 
    Vadim Alexandre, Rob Rees (Sales and 
    Broking) 
 
    Panmure Gordon (UK) Limited (Joint           Tel: +44 (0) 20 7886 
    Broker)                                      2500 
   Rupert Dearden/Freddy Crossley/Emma 
    Earl 
 
    Consilium Strategic Communications 
   Mary-Jane Elliott, Namrata Taak,             Tel: +44 (0) 20 3709 5700 
    Max Bennett, Emmalee Hoppe                   Email: Bivictrix@consilium-comms.com

About BiVictriX Therapeutics plc

BiVictriX (AIM: BVX) is an emerging biotechnology company leveraging clinical experience and its proprietary discovery engine to advance a new class of highly cancer-selective, next-generation precision cancer therapies in one of the fastest-growing markets in oncology. BiVictriX's first-in-class Bi-Cygni(R) Antibody Drug Conjugates (ADCs) combine superior efficacy with substantially improved cancer-selectivity and safety to provide opportunities for prolonged dosing and greater efficacy in the clinic. The Company is advancing its pipeline to deliver the future of cancer care across a broad range of haematological and solid cancer indications in areas of high unmet medical need.

Find out more at www.bivictrix.com and connect with us on LinkedIn and Twitter @BiVictriX .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROMQVLFBXVLFBBE

(END) Dow Jones Newswires

August 08, 2023 12:18 ET (16:18 GMT)

Bivictrix Therapeutics (LSE:BVX)
過去株価チャート
から 4 2024 まで 5 2024